The technical assistance (TA) will support the Kingdom of Cambodia in building resilience within, and improving the competitiveness of the country's private sector by enhancing the capacity of state institutions to support adoption of digital technologies and to foster innovation and diversification in micro-, small- and medium-sized enterprises (MSMEs), where women entrepreneurs and workers are traditionally prevalent.

The technical assistance (TA), which will be approved with the proposed Integrated Water Resources Management Project, will help the Ministry of Water Resources and Meteorology: (i) implement one of the activities of output 2 (para 6), (ii) inform rice farmers about and train them to implement innovative climate mitigative water management technology, and (iii) disseminate this innovative AWD technology to the entire country. The TA project's demonstration activities are expected to reduce emissions by 11,750 tons of carbon dioxide equivalent.

1. Output 1: Quality of STEM education with support of technology improved.

From migrating sauropods and semi-aquatic predators to doting parents, palaeontologists are finally uncovering the mysteries of the lifestyles of dinosaurs

Taiwan’s first ever minister of digital affairs has transformed politics, using online platforms and AI to give power to the country’s citizens – with lessons for us all

To even out the intermittent power supply from wind and solar, we need to build vast energy storage facilities. It turns out the best solution might be cheap, simple ideas like heating bricks and lifting weights

Many fear that voters are being manipulated by political campaigns that use Facebook ads, TikTok and YouTube videos, but research reveals a more surprising story

From migrating sauropods and semi-aquatic predators to doting parents, palaeontologists are finally uncovering the mysteries of the lifestyles of dinosaurs

Title: Qigong Meditation for Beginners: Techniques, Benefits, and More
Category: Health and Living
Created: 8/24/2022 12:00:00 AM
Last Editorial Review: 8/24/2022 12:00:00 AM

Title: Are High-Tech Blood Pressure Monitors Really Worth It?
Category: Health News
Created: 8/16/2022 12:00:00 AM
Last Editorial Review: 8/16/2022 12:00:00 AM

Background

In adults with serious respiratory illness, breathlessness is prevalent and associated with reduced health-related quality of life. The aim of this review was to assess the impact of breathing techniques on breathlessness in adults with serious respiratory illness.

Purpose The posterior superior alveolar (PSA) block injection is one of many techniques used to provide profound anesthesia for invasive dental procedures. This technique has a high success rate but is not without complication risks. The purpose of this study was to determine if pulpal anesthesia of the maxillary second molar could be achieved using a reduced needle depth of 10mm or 5mm compared to the traditional needle depth of 16mm.Methods Sixty participants were asked to participate in three sessions. Each session started with a pre neural response test, followed by one randomized needle depth PSA injection, and ending with a post neural response test. The neural response test consisted of two parts, a cold refrigerant and a dental probe, on the buccal and interproximal surface of the maxillary second molar. After receiving a positive neural response, each participant received a posterior superior alveolar block injection using a short (21mm), 27-gauge dental needle with a randomized needle penetration depth of 16mm, 10mm, or 5mm. A post neural response test consisting of the same two parts as the pre-test was conducted on the maxillary second molar to evaluate for profound anesthesia.Results Positive neural responses were obtained from 100% of the participants (n=167) during the pre-tests. Study results demonstrated an 85% success rate at the traditional 16mm needle depth and a 93% and 92% success rates for the reduced needle depths of 10mm and 5mm, respectively. Pulpal anesthesia of the maxillary second molar had been achieved at all three needle depths with no statistically significant difference in the rate of success. Furthermore, there were no adverse events observed.Conclusion The reduced needle depth technique showed promise in achieving desired results of pulpal anesthesia with a reduced risk for complications associated with the PSA block injection. Additional studies are recommended to achieve evidence-based support for this reduced needle depth technique.

ATP-binding cassette transporter subfamily G member 2 (ABCG2) is a membrane-bound transporter responsible for the efflux of various xenobiotics and endobiotics, including protoporphyrin IX (PPIX), an intermediate in the heme biosynthesis pathway. Certain genetic mutations and chemicals impair the conversion of PPIX to heme and/or increase PPIX production, leading to PPIX accumulation and toxicity. In mice, deficiency of ABCG2 protects against PPIX-mediated phototoxicity and hepatotoxicity by modulating PPIX distribution. In addition, in vitro studies revealed that ABCG2 inhibition increases the efficacy of PPIX-based photodynamic therapy by retaining PPIX inside target cells. In this review, we discuss the roles of ABCG2 in modulating the tissue distribution of PPIX, PPIX-mediated toxicity, and PPIX-based photodynamic therapy.

The regulation of drug-metabolizing enzymes and transporters by cytokines has been extensively studied in vitro and in clinic. Cytokine-mediated suppression of cytochrome P450 (CYP) or drug transporters may increase or decrease the systemic clearance of drug substrates that are primarily cleared via these pathways; neutralization of cytokines by therapeutic proteins may thereby alter systemic exposures of such drug substrates. The Food and Drug Administration recommends evaluating such clinical drug interactions during clinical development and has provided labeling recommendations for therapeutic proteins. To determine the clinical relevance of these drug interactions to dose adjustments, trends in steady-state exposures of CYP-sensitive substrates coadministered with cytokine modulators as reported in the University of Washington Drug Interaction Database were extracted and examined for each of the CYPs. Coadministration of cytochrome P450 family 3 subfamily A (CYP3A) (midazolam/simvastatin), cytochrome P450 subfamily 2C19 (omeprazole), or cytochrome P450 subfamily 1A2 (caffeine/tizanidine) substrates with anti-interleukin-6 and with anti-interleukin-23 therapeutics led to changes in systemic exposures of CYP substrates ranging from ~ –58% to ~35%; no significant trends were observed for cytochrome P450 subfamily 2D6 (dextromethorphan) and cytochrome P450 subfamily 2C9 (warfarin) substrates. Although none of these changes in systemic exposures have been reported as clinically meaningful, dose adjustment of midazolam for optimal sedation in acute care settings has been reported. Simulated concentration-time profiles of midazolam under conditions of elevated cytokine levels when coadministered with tocilizumab, suggest a ~six- to sevenfold increase in midazolam clearance, suggesting potential implications of cytokine–CYP drug interactions on dose adjustments of sensitive CYP3A substrates in acute care settings. Additionally, this article also provides a brief overview of nonclinical and clinical assessments of cytokine–CYP drug interactions in drug discovery and development.

The precision medicine initiative has driven a substantial change in the way scientists and health care practitioners think about diagnosing and treating disease. While it has long been recognized that drug response is determined by the intersection of genetic, environmental, and disease factors, improvements in technology have afforded precision medicine guided dosing of drugs to improve efficacy and reduce toxicity. Pharmacometabolomics aims to evaluate small molecule metabolites in plasma and/or urine to help evaluate mechanisms that predict and/or reflect drug efficacy and toxicity. In this mini review, we provide an overview of pharmacometabolomic approaches and methodologies. Relevant examples where metabolomic techniques have been used to better understand drug efficacy and toxicity in major depressive disorder and cancer chemotherapy are discussed. In addition, the utility of metabolomics in drug development and understanding drug metabolism, transport, and pharmacokinetics is reviewed. Pharmacometabolomic approaches can help describe factors mediating drug disposition, efficacy, and toxicity. While important advancements in this area have been made, there remain several challenges that must be overcome before this approach can be fully implemented into clinical drug therapy.

A STING (stimulator of interferon genes) agonist GSK3996915 under investigation in early discovery for hepatitis B was orally dosed to a mouse model for understanding the parent drug distribution in liver, the target organ. Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) was used to quantify the distribution of GSK3996915 in liver collected from mice administered a single oral dose at 90 mg/kg. GSK3996915 was detected with a zonal distribution localized in the portal triad and highly concentrated in the main bile ducts, indicating clearance through biliary excretion. High spatial resolution imaging showed the distribution of the parent drug localized to the cellular populations in the sinusoids, including the Kupffer cells. Additionally, a series of drug-related metabolites were observed to be localized in the central zones of the liver. These results exemplify the potential of utilizing MALDI IMS for measuring not only quantitative drug distribution and target exposure but also drug metabolism and elimination in a single suite of experiments.

Drug–drug interaction (DDI) assessment of therapeutic peptides is an evolving area. The industry generally follows DDI guidelines for small molecules, but the translation of data generated with commonly used in vitro systems to in vivo is sparse. In the current study, we investigated the ability of advanced human hepatocyte in vitro systems, namely HepatoPac, spheroids, and Liver-on-a-chip, to assess potential changes in regulation of CYP1A2, CYP2B6, CYP3A4, SLCO1B1, and ABCC2 in the presence of selected therapeutic peptides, proteins, and small molecules. The peptide NN1177, a glucagon and GLP-1 receptor co-agonist, did not suppress mRNA expression or activity of CYP1A2, CYP2B6, and CYP3A4 in HepatoPac, spheroids, or Liver-on-a-chip; these findings were in contrast to the data obtained in sandwich cultured hepatocytes. No effect of NN1177 on SLCO1B1 and ABCC2 mRNA was observed in any of the complex systems. The induction magnitude differed across the systems (e.g., rifampicin induction of CYP3A4 mRNA ranged from 2.8-fold in spheroids to 81.2-fold in Liver-on-a-chip). Small molecules, obeticholic acid and abemaciclib, showed varying responses in HepatoPac, spheroids, and Liver-on-a-chip, indicating a need for EC₅₀ determinations to fully assess translatability data. HepatoPac, the most extensively investigated in this study (3 donors), showed high potential to investigate DDIs associated with CYP regulation by therapeutic peptides. Spheroids and Liver-on-a-chip were only assessed in one hepatocyte donor and further evaluations are required to confirm their potential. This study establishes an excellent foundation toward the establishment of more clinically-relevant in vitro tools for evaluation of potential DDIs with therapeutic peptides.

Pregnane X receptor (PXR) belongs to the nuclear receptor superfamily that plays a crucial role in hepatic physiologic and pathologic conditions. Phase separation is a process in which biomacromolecules aggregate and condense into a dense phase as liquid condensates and coexist with a dilute phase, contributing to various cellular and biologic functions. Until now, whether PXR could undergo phase separation remains unclear. This study aimed to investigate whether PXR undergoes phase separation. Analysis of the intrinsically disordered regions (IDRs) using algorithm tools indicated a low propensity of PXR to undergo phase separation. Experimental assays such as hyperosmotic stress, agonist treatment, and optoDroplets assay demonstrated the absence of phase separation for PXR. OptoDroplets assay revealed the inability of the fusion protein of Cry2 with PXR to form condensates upon blue light stimulation. Moreover, phase separation of PXR did not occur even though the mRNA and protein expression levels of PXR target, cytochrome P450 3A4, changed after sorbitol treatment. In conclusion, for the first time, these findings suggested that exogenous PXR does not undergo phase separation following activation or under hyperosmotic stress in nucleus of cells.

Protein abundance data of drug-metabolizing enzymes and transporters (DMETs) are useful for scaling in vitro and animal data to humans for accurate prediction and interpretation of drug clearance and toxicity. Targeted DMET proteomics that relies on synthetic stable isotope-labeled surrogate peptides as calibrators is routinely used for the quantification of selected proteins; however, the technique is limited to the quantification of a small number of proteins. Although the global proteomics-based total protein approach (TPA) is emerging as a better alternative for large-scale protein quantification, the conventional TPA does not consider differential sequence coverage by identifying unique peptides across proteins. Here, we optimized the TPA approach by correcting protein abundance data by the sequence coverage, which was applied to quantify 54 DMETs for characterization of 1) differential tissue DMET abundance in the human liver, kidney, and intestine, and 2) interindividual variability of DMET proteins in individual intestinal samples (n = 13). Uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7), microsomal glutathione S-transferases (MGST1, MGST2, and MGST3) carboxylesterase 2 (CES2), and multidrug resistance-associated protein 2 (MRP2) were expressed in all three tissues, whereas, as expected, four cytochrome P450s (CYP3A4, CYP3A5, CYP2C9, and CYP4F2), UGT1A1, UGT2B17, CES1, flavin-containing monooxygenase 5, MRP3, and P-glycoprotein were present in the liver and intestine. The top three DMET proteins in individual tissues were: CES1>CYP2E1>UGT2B7 (liver), CES2>UGT2B17>CYP3A4 (intestine), and MGST1>UGT1A6>MGST2 (kidney). CYP3A4, CYP3A5, UGT2B17, CES2, and MGST2 showed high interindividual variability in the intestine. These data are relevant for enhancing in vitro to in vivo extrapolation of drug absorption and disposition and can be used to enhance the accuracy of physiologically based pharmacokinetic prediction of systemic and tissue concentration of drugs.

Hydrolases represent an essential class of enzymes indispensable for the metabolism of various clinically essential medications. Individuals exhibit marked differences in the expression and activation of hydrolases, resulting in significant variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs metabolized by these enzymes. The regulation of hydrolase expression and activity involves both genetic polymorphisms and nongenetic factors. This review examines the current understanding of genetic and nongenetic regulators of six clinically significant hydrolases, including carboxylesterase (CES)-1 CES2, arylacetamide deacetylase (AADAC), paraoxonase (PON)-1 PON3, and cathepsin A (CTSA). We explore genetic variants linked to the expression and activity of the hydrolases and their effects on the PK and PD of their substrate drugs. Regarding nongenetic regulators, we focus on the inhibitors and inducers of these enzymes. Additionally, we examine the developmental expression patterns and gender differences in the hydrolases when pertinent information was available. Many genetic and nongenetic regulators were found to be associated with the expression and activity of the hydrolases and PK and PD. However, hydrolases remain generally understudied compared with other drug-metabolizing enzymes, such as cytochrome P450s. The clinical significance of genetic and nongenetic regulators has not yet been firmly established for the majority of hydrolases. Comprehending the mechanisms that underpin the regulation of these enzymes holds the potential to refine therapeutic regimens, thereby enhancing the efficacy and safety of drugs metabolized by the hydrolases.

BACKGROUND AND PURPOSE:

Angioplasty and stent placement have been described as a bailout technique in individuals with failed thrombectomy. We aimed to investigate Stent retriever AssIsted Lysis (SAIL) with tirofiban before angioplasty and stent placement.

BACKGROUND AND PURPOSE:

Reocclusion after treatment is a concern in endovascular therapy for isolated intracranial atherothrombotic stroke-related large-vessel occlusion (AT-LVO). However, the optimal endovascular therapy technique for AT-LVO has not yet been investigated. This study evaluated the optimal endovascular therapy technique for AT-LVO in a real-world setting.

PURPOSE

We undertook a trial to test the efficacy of a technology-assisted health coaching intervention for weight management, called Goals for Eating and Moving (GEM), within primary care.

THE world’s tech will undergo a transformation over just three weeks with a bonanza of new phones, tablets, smart watches and OLED 4K TVs.

There’s plenty that you could justifiably expect from a Bioware RPG: chats with mates, opportunities to get those mates horribly killed, surviving mates turning to the side then walking offscreen. But I don’t think anyone expected Dragon Age: The Veilguard to be, at least on a purely technical level, one of the smoothest-performing, settings-rich AAA PC releases of the year so far.

Read more

In a basement beneath City St George's, University of London, senior NATO leaders watch on as four research teams demonstrate the latest in AI-controlled, autonomous drone technolo0gy

‘Battle of Technologies’ sees electric vehicles and combustion cars compete at the highest level. Who will win?

The 2024 Nobel prize in physics has gone to John Hopfield and Geoffrey Hinton for discoveries that enabled machine learning and are key to the development of artificial intelligence models like ChatGPT

A biologist at Cape Breton University is hoping a piece of technology used to keep people safe in the pandemic can help protect Nova Scotia's oysters against the effects of warming waters.

NASA reconnected with Voyager 1, which is located nearly 15 billion miles away from Earth, after a brief pause that triggered the spacecraft's fault protection system.

Scientists from the Leibniz Zentrum für Archäologie and Durham University have examined a collection of 406 engraved schist plaquettes found at the Magdalenian site of Gönnersdorf in Germany.

The post 15,800-Year-Old Engraved Plaquettes Shed Light on Paleolithic Fishing Techniques appeared first on Sci.News: Breaking Science News.

New technologies will radically change the experience of living with and caring for someone with Alzheimer's, says Professor Fiona Carragher, chief policy and research officer at Alzheimer's Society, UK

<a href="https://bluetechker.com/" rel="nofollow ugc">Blue Techker</a> Nice post. I learn something totally new and challenging on websites

<a href="https://bluetechker.com/" rel="nofollow ugc">Blue Techker</a> naturally like your web site however you need to take a look at the spelling on several of your posts. A number of them are rife with spelling problems and I find it very bothersome to tell the truth on the other hand I will surely come again again.

Humans perfected how to identify wild animals over millennia, and now biologists are rediscovering the exceptional worth of the tracks and marks left behind

In the bustling world of the restaurant industry, standing out is more challenging than ever. With diners increasingly turning to the internet to discover their next meal, having a strong online presence is crucial. This guide will show you practical tips and techniques to maximise your restaurant’s online visibility and enhance your SEO efforts. By […]

The post Maximising Online Visibility and SEO for Restaurants: Tips and Techniques appeared first on Chart Attack.

Chinese business people may be able to find creative ways to avoid U.S. tariffs, but for Beijing, its concerns for the incoming Trump presidency go beyond trade.

A year after going private in a $6.5 billion private equity deal, software maker New Relic is into its second round of layoffs this year.

Sacramento-based Zennify, a tech consulting firm for financial service companies, has acquired Terazo, a digital engineering firm based in Richmond, Virginia.

Rivian is teaming up with Volkswagen in a $5.8 billion joint venture for EV innovation on its R2 model, which the company says will eventually be manufactured in Georgia.

2024 has been a rough year for Sonos. The company’s would-be triumphant entry into the crowded headphones market was overshadowed by a disastrous app redesign. In the fallout of the botched software update, the company decided to delay products that were ready to be shipped to give itself more time to right the course. Consumer trust eroded, and people who already owned Sonos gear were living in a cycle of constant frustration.

Thanks to a number of rumors, we already knew that one of the pending product releases was the Arc Ultra ($999). A few weeks ago the company decided not to wait any longer to reveal it. While the design is mostly unchanged from the Arc that debuted in 2020, there are several key changes on the inside that make this a better all-in-one solution for people who don’t want to add more speakers to their living room setup. Sonos is promising better bass performance thanks to new speaker tech that’s debuting in the Arc Ultra, but just how good can it be?

Design

The refined design of the original Arc was a massive upgrade from that of the Playbar, and showed a progression from Sonos’ compact Beam soundbar. Honestly, the aesthetic is pretty timeless, in my opinion, and it’s a look that should age well for years to come. That said, it makes sense that Sonos would keep the design for the Arc Ultra, only making some minor changes to the exterior.

The Arc Ultra still comes in both black and white options, allowing you to choose what looks best in your living room or home theater. Sonos updated the controls to mirror what’s available on the newer Era 100 and Era 300 speakers, moving them to a top-facing bar at the back. There’s a volume slider on the right with play/pause and skip controls in the center. On the left side, Sonos gives you a microphone control so you can mute the built-in mics as needed.

And that’s really it in terms of design changes that you can see. The Arc Ultra is slightly shorter height-wise than the Arc, and it’s a little wider than its predecessor. Neither of which make a huge difference, and they won’t drastically change how you position the speaker beneath your TV.

Inside, Sonos has re-engineered the Arc Ultra to improve audio performance. The biggest piece of this overhaul is the new Sound Motion woofer that enables better bass performance before you add a standalone wireless sub. The achievement here, thanks to the acquisition of audio company Mayht, is that the new component lays flat, taking up less room than a traditional cone-shaped woofer. The Sound Motion driver also helps deliver increased clarity and depth, on top of doubling the bass output of the original Arc.

Sonos redesigned the entire acoustic architecture of the Arc Ultra during the process of adding the Sound Motion woofer. The soundbar now houses three more drivers than the arc, a list that includes seven tweeters (two of which are upfiring), six mid-range drivers (midwoofers, as Sonos calls them) and the aforementioned woofer for a total of 14. The company also employs 15 Class-D digital amplifiers along with far-field mics for tuning and voice control.

There’s still only a single HDMI (eARC) port, which allows most modern TVs the ability to control the soundbar’s volume and mute options from your TV remote. Moreover, the Arc Ultra is compatible with Wi-Fi 6 and newly-added Bluetooth 5.3 connectivity allows you to stream from any device. And of course, AirPlay 2 is still on the spec sheet. One last thing I’ll mention here is that the Arc Ultra doesn’t ship with an optical adapter if you prefer that connection. The company will sell you one for $25.

Software and features

Since the Arc Ultra is a Sonos product, there are a lot of core features that are the same as they are on the company’s other devices. You can use the soundbar as part of a multiroom setup and Trueplay tuning is here to adjust the audio to the acoustics of the room. There’s still an adjustable EQ with options for bass, treble and loudness and a Night Sound mode makes things less boomy when someone in your house may be trying to work or sleep.

While Trueplay will give you the best sound customization for the sonic characteristics of your living room, Sonos is enabling a Quick Tune feature for the first time on the Arc Ultra. Here, the soundbar will use its internal mics, as opposed to your phone, to offer a certain degree of improvement. The company says it wanted to give people the option of something quicker than Trueplay, although the full-fledged tuning process doesn’t take very long at all.

Speech Enhancement has been a handy feature on Sonos soundbars for a while, giving you the ability to improve dialog clarity as needed. Before now, it was an all-or-nothing feature, but on the Arc Ultra, the company introduced three levels of speech boost to give you more options to better suit your needs. This means the soundbar can help you hear clearly over background noise or simply follow along better by elevating dialog above the rest of the soundtrack mix.

The trademark feature of Sonos’ Ace headphones is the ability to beam the audio from a compatible soundbar to the cans for a private home theater. That TV Audio Swap tool is available on the Arc Ultra, so you can instantly send the sound to the headphones with the press of a button. In fact, Sonos bundles the Arc Ultra and Ace headphones in a $1,373 set. What’s more, the Ace supports spatial audio with dynamic head tracking, so you can count on immersive sound even when you’re employing it on an individual basis.

Despite all of the problems that Sonos has had with its app, some of which it's still working to resolve, I didn't encounter any issues during my testing. The software crashed on me once when the Trueplay tuning process completed, but everything had already run its course and I didn’t have to repeat it. Other than that, the app has worked reliably over the last week while I’ve been putting the Arc Ultra through its paces. Most importantly, the software is stable and the full suite of controls for the new soundbar is available at launch.

Sound performance

The original Arc already sounded great, so Sonos really had its work cut out for it to further improve the audio quality for the Arc Ultra. Thanks to the improved bass of the Sound Motion tech, a change that also takes up less space, the company says it had the ability to then overhaul the mid-range and high-frequency components as well. By using multiple sizes of mid-range drivers and tweeters, Sonos was able to tweak the speaker positioning inside of the soundbar for improved projection and more immersive sound.

In addition to the enhanced bass performance, the second thing that was immediately apparent on the Arc Ultra was those improvements to the dimensional sound. Whether it was a quidditch match in a Harry Potter movie or zooming F1 cars in Drive to Survive, the soundbar now has better directional, immersive sound than its predecessor. Sonos says the Arc Ultra now renders Dolby Atmos content in a 9.1.4-channel setup, versus 5.0.2 with the Arc, which further contributes to the enveloping audio. Interestingly, I haven’t seen any of the competition claim four up-firing channels from the soundbar like Sonos does here (those that do are usually accounting for up-firing drivers in the rear speakers). You can really hear the difference from the second you fire up the Arc Ultra, and the effect is consistent across content sources.

The increased bass performance makes the Arc Ultra a much better speaker for music without a separate subwoofer. You won’t get the bombastic low-end tone the newly updated Sonos Sub 4 can produce, but there’s enough from the soundbar to give Kaytranada’s Timeless, Phantogram’s Memory of a Day and Bilmuri’s American Motor Sports plenty of booming backbone when a track demands it. There’s also still the trademark Sonos clarity I’ve come to expect over the years, which means finer details like the texture of synths, layered guitars and the nuance of acoustic instruments cut through the mix cleanly.

And speaking of clarity, the company’s new Speech Enhancement settings are also a big improvement. Being able to select how much of a boost this feature offered depending on either my needs right then or based on the overall tuning of the content is really nice. It allowed me to max out the dialog when watching movies after my toddler was asleep so that speech didn’t suffer when sound effects were louder during intense scenes of The Hobbit: An Unexpected Journey.

The competition

There’s no doubt the Arc Ultra packs in deeper, more immersive sound than its predecessor, but some people will still want a more robust setup to wring every ounce of audio out of a Sonos living room setup. The high-end choice for this is what Sonos calls the Ultimate Immersive Set, which includes the Arc Ultra, two Era 300s and the Sub 4. Right now, that will cost you $2,561. For something less expensive, you can get the Arc Ultra and the new Sub 4 (normally $799) for $1,708 (Premium Entertainment Set). And therein lies the biggest problem with Sonos soundbars: expanding your living room setup to get the most immersive experience gets very pricey very quickly when the centerpiece is already $999.

If you can live without all the conveniences of Sonos products, you can get an all-in-one package from Samsung for $1,500. With the Q990D, you’ll get the soundbar, two rear speakers and a wireless subwoofer in the same box. The setup offers 11.1.4 audio for excellent Atmos sound, thanks in part to up-firing drivers in the rear speakers. Samsung offers a host of handy features, from Q-Symphony audio with TV speakers, SpaceFit Sound Pro room calibration, Adaptive Sound audio enhancement, a dedicated gaming mode and more. The Q990D remains my top pick for the best soundbars for a lot of reasons, a key one being everything you could need comes in one all-inclusive package.

Wrap-up

The Arc Ultra is an obvious improvement over the Arc in the sonic department. New technology delivers on its promise to boost bass, clarity and immersive before you start adding extra components. Expanded features like Speech Enhancements and a quick-tune option offer new tools for dialing in the sound, while the stock Sonos experience remains intact. And thankfully, that includes an app that’s more stable than it was a few months ago. The Arc Ultra is still pricey at $999, but it exhibits a lot more sonic prowess than its predecessor for only $100 more.

Indian pharma and biotech companies are confident that under the new US President Donald Trump, its strengths in high quality generics manufacture and export will continue to command respect. This view is

Oversimplification about integration of traditional and modern treatment systems often creates confusion among the stakeholders, and nobody understands the reality of the integration and what it is meant for, said Dr.

The National Accreditation Board for Testing and Calibration Laboratories (NABL), under the Quality Council of India (QCI), has announced a collaborative effort with Man─Made Textile Research Association (MANTRA) in Surat to deliver a specialized technical training programme on medical textiles testing.

WITTMANN BATTENFELD will present the latest solutions for time and cost optimisation in the production of parts with nano structures at Compamed, booth No. F03-1 in hall 8b.

The Association of British HealthTech Industries (ABHI) is excited to unveil a diverse delegation of UK HealthTech innovators at MEDICA 2024, one of the world's largest and most influential medical trade fairs.

In this episode of The FemTech series Olivia Friett is joined by Jane Kennedy and Dr. MaryAnn Ferreux where we will discuss the inequality in women's health and how we can overcome the obstacles that come with this.

Charco Neurotech, a medtech company based in the United Kingdom, has developed CUE1, a non-invasive wearable that is intended to assist those with Parkinson’s disease to manage their motor symptoms. The device is typically affixed to the sternum, and provides vibratory action in a focused region of the body. The technology is based on the […]